E2F1 Recombinant Monoclonal Antibody

Code CSB-RA826096A0HU
Size US$210
Order now
Image
  • Western Blot
    Positive WB detected in: Jurkat whole cell lysate, PC-3 whole cell lysate, Rat Heart tissue
    All lanes: E2F1 antibody at 1:2000
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 47 kDa
    Observed band size: 60 kDa
  • IHC image of CSB-RA826096A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • IHC image of CSB-RA826096A0HU diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
  • Immunofluorescence staining of Hela Cells with CSB-RA826096A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
  • Overlay histogram showing Hela cells stained with CSB-RA826096A0HU (red line) at 1:50. The cells were fixed with 70% Ethylalcohol (18h) and then incubated in 10% normal goat serum to block non-specific protein-protein interactions followedby the antibody (1µg/1*106 cells) for 1 h at 4℃.The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 30min at 4℃. Control antibody (green line) was Rabbit IgG (1µg/1*106 cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
E2F1
Alternative Names
Transcription factor E2F1 (E2F-1) (PBR3) (Retinoblastoma-associated protein 1) (RBAP-1) (Retinoblastoma-binding protein 3) (RBBP-3) (pRB-binding protein E2F-1), E2F1, RBBP3
Species Reactivity
Human, Rat
Immunogen
A synthesized peptide derived from human E2F1
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
1D12
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, WB, IHC, IF, FC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
IF 1:20-1:200
FC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The E2F1 recombinant monoclonal antibody can be used to detect both human and rat E2F1 proteins in five assays including ELISA, WB, IHC, IF, and FC. It is produced using recombinant DNA technology. The gene that codes for the E2F1 monoclonal antibody is synthesized after sequencing the cDNA of the E2F1 antibody-producing hybridomas. The hybridomas are created by fusing myeloma cells with B cells isolated from an animal that has been immunized with a synthesized peptide derived from human E2F1. The synthesized gene is then incorporated into a vector and transfected into cells for cultivation. The resulting E2F1 recombinant monoclonal antibody is purified through affinity chromatography from the cell culture supernatant.

The E2F1 protein is a transcription factor that plays a key role in regulating the cell cycle and cell proliferation. E2F1 can activate the expression of genes required for progression through the G1/S phase transition of the cell cycle, including genes involved in DNA replication, DNA repair, and cell division. In addition, E2F1 can induce apoptosis in response to DNA damage or other stress signals. Dysregulation of E2F1 activity has been implicated in a variety of diseases, including cancer and developmental disorders.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters. Positively regulates transcription of RRP1B.
Gene References into Functions
  1. XPC is an RNA polymerase II cofactor recruiting ATAC coactivator complex to promoters by interacting with E2F1. PMID: 29973595
  2. Our findings reveal that the rs3213173 (C/T) and rs3213176 (G/A) polymorphisms of the E2F1 gene are genetic risk factors for susceptibility to lung cancer and Head and Neck cancer in the North Indian Population. PMID: 30036075
  3. High E2F1 expression is associated with hepatocellular carcinoma progression. PMID: 30106440
  4. the expression of miR175p inhibited high glucoseinduced endothelial cell injury by targeting E2F1. PMID: 29786752
  5. The nuclear transcription factor Y subunit beta (NFYB)-E2F transcription factor 1 (E2F1) pathway displays a crucial role in the chemoresistance ofoxaliplatin-resistant colorectal cancer (OR-CRC) by inducing the expression and activation of checkpoint kinase 1 (CHK1), suggesting a possible therapeutic target for oxaliplatin resistance in CRC. PMID: 29203250
  6. If, as expected, the consequences of the deregulation of the CDKN1C-E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential therapeutic strategies in human Precursor T-cell lymphoblastic lymphomas PMID: 29661169
  7. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2positive breast cancer. PMID: 29845287
  8. Data show that mRNA translation stress induces E2F transcription factor 1 (E2F1) via PI3-kinase p110 subunit delta (PI3Kdelta). PMID: 29235459
  9. PPM1B plays a negative role in the activation of the p38-RB1-E2F1 pathway and that targeting PPM1B could be useful in certain types of cancer by stimulating chemotherapy-induced cell death. PMID: 29654756
  10. Studied impact of BET proteins and E2F transcription factor 1 (E2F1) in neoplastic genetic transcription in glioblastoma. PMID: 29764999
  11. E2F1 knockdown decreased the expression of discoidin domain receptor 1 (DDR1) which plays a crucial role in many fundamental processes such as cell differentiation, adhesion, migration and invasion. PMID: 29039472
  12. Our data imply that downregulation of E2F1 may be a key factor in the celastrol-mediated inhibitory effects in HepG2 cells, and celastrol can serve as a leading compound for the development of compounds designed to inactivate E2F1 for hepatocellular carcinoma therapy PMID: 29048668
  13. SNHG16 promotes glioma tumorigenesis by sponging miR-20a-5p, leading to the enhancement of its endogenous targets E2F1 PMID: 29685003
  14. These results demonstrate that gambogic acid sensitizes pancreatic cancer cells to gemcitabine in vitro and in vivo by inhibiting the activation of the ERK/E2F1/RRM2 signaling pathway. PMID: 28797284
  15. Reports showed that high expression of the transcription factor E2F1 was involved in the invasion and metastasis of small cell lung cancer (SCLC). Further results provided evidence that E2F1 promoted EMT by regulating ZEB2 gene expression in SCLC. PMID: 29115924
  16. By comparison in HeLa, Dox induced apoptosis through upregulation of endogenous E2F1 involving post-transcriptional mechanisms, while E2F6 was down regulated with induction of the Checkpoint kinase-1 and proteasome degradation. These data imply that E2F6 serves to modulate E2F activity and protect cells including cardiomyocytes from apoptosis and improve survival. PMID: 28964969
  17. This study reveals a molecular pathway involving lncRNA GAS5/E2F1/P27(Kip1) which regulates cell proliferation and could be a potential therapeutic target in prostate cancer. PMID: 28396462
  18. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. PMID: 28569791
  19. Data show that lncRNA-HIT acted as an oncogene through association with E2F transcription factor 1 protein (E2F1). PMID: 28429752
  20. Cell proliferation and apoptosis were almost completely abolished in the PAa cells cotreated with TRIM28 siRNA and etoposide following knockdown of E2F1. The results of our study demonstrated that the combination of TRIM28 siRNA and etoposide may be effective against nonsmall cell lung cancer (NSCLC)and has the potential of being a new therapeutic tool for future treatment. PMID: 28498400
  21. These results reveal an additional level of regulation of the stability and the activity of E2F1 by a non-degradative K63-poly-ubiquitination and uncover a novel function for the E3-ubiquitin ligase cIAP1. PMID: 28542143
  22. Higher levels of miR-135a in gastric cancer (GC) are associated with shorter survival times and reduced times to disease recurrence. The mechanism whereby miR-135a promotes GC pathogenesis appears to be the suppression of E2F1 expression. PMID: 27683111
  23. Results provide mechanistic insight into a series of complex, differentiation-specific molecular mechanisms that regulate E2F1 during keratinocyte maturation via multiple events. These events include nucleocytoplasmic transport and changes in ubiquitinylation patterns specifically orchestrated through S403 and T433, and which differ from other mechanisms that regulate E2F1 turnover in undifferentiated cells. PMID: 27903963
  24. these results suggest that the E2F1/miR19a/PPARalpha feedback loop is critical for glioma progression PMID: 27835866
  25. This study suggests for the first time an involvement of E2F1 copy number variations in testicular germ cell tumor susceptibility and supports previous preliminary data on the importance of AKT/mTOR signaling pathway in this cancer. PMID: 28104681
  26. High E2F1 expression is associated with gastric cancer. PMID: 27036039
  27. Data suggest that the protein arginine methyltransferase 5 (PRMT5)-E2F1 transcription factor (E2F-1) pathway may act as a common target for exogenous lectins including Anguilla japonica lectin 1 (AJL1), and the cellular response to exogenous AJL1 may suggest a novel agent for cancer gene therapy. PMID: 26990556
  28. The low level E2F1 are sufficient to induce numerous cell cycle-promoting genes, intermediate levels induce growth arrest genes (i.e., p18, p19 and p27), whereas higher levels are necessary to induce key apoptotic E2F1 targets APAF1, PUMA, HRK and BIM. PMID: 28211871
  29. This review focuses on the relationship between E2F1, growth factors and cytokines. PMID: 26947516
  30. that E2F1 mRNA stability and E2F1 protein levels are reduced in cells lacking RALY expression PMID: 28972179
  31. our results indicate that E2F1 is an important downstream gene of ISX in hepatoma progression. PMID: 27175585
  32. found that human E2F1 competes with YAP for TEAD1 binding, affecting YAP activity, indicating that this mode of cross-regulation is conserved PMID: 29207260
  33. E2F1-mediated hPOMC transcription is a potential target for suppressing ACTH production in ectopic Cushing's syndrome. PMID: 27935805
  34. Results suggest that E7 recruited CUL2, driven by CUL2/E2F1/miR-424 regulatory loop, is overexpressed and accelerates HPV16-induced cervical carcinogenesis. PMID: 27153550
  35. Results demonstrated that E2F-1 mediated PEG10 overexpression promotes pancreatic cancer cell proliferation via accelerating cell cycle progression and increase migration and invasion through ERK/MMP7 pathway. PMID: 28193232
  36. We conclude that high expression of S18-2 and free E2F...1might be a good set of prognostic markers for endometrial cancer PMID: 26959119
  37. COMMD9 participates in TFDP1/E2F1 activation and plays a critical role in non-small cell lung cancer. PMID: 27871936
  38. Using iterative experimental and computational analyses, the authors show physical and functional interactions between NF-kappaB and the E2 Factor 1 (E2F-1) and E2 Factor 4 (E2F-4) cell cycle regulators. PMID: 27185527
  39. Heavy ion irradiation could induce p53(-/-) hepatoma cells to undergo apoptosis via E2F1/Bax/Casp3 signaling pathway. PMID: 28500630
  40. Propose that E2F1 interacts with BRCA1 indirect pathway to induce two different small molecule metabolic pathways or cell cycle regulation pathways in hepatocellular carcinoma. PMID: 28474358
  41. The pyruvate dehydrogenase kinases (PDKs) PDK1 and PDK3 are direct targets of KDM4A and E2F1 and modulate the switch between glycolytic metabolism and mitochondrial oxidation. PMID: 27626669
  42. Taken together, this study reveals evidence demonstrating a mechanism by which the LPR6/ GSK3beta/E2F1 axis-upregulated LSH promoted gliomas. PMID: 28042322
  43. High E2F1 expression is associated with melanoma. PMID: 28068326
  44. p63alpha protein up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9 signaling and bladder cancer invasion PMID: 28794159
  45. E2F1 couples immune cell development to immune response.E2f1 role in the inflammation-associated cancers [review] PMID: 26881929
  46. These data suggest a model in which cells experiencing oncogene-induced replication stress through deregulation of E2F-dependent transcription. PMID: 27160911
  47. Describe a regulatory loop miR-218-CDK6/CyclinD1-E2F1 whose disruption may contribute to cell cycle progression in gastric cancer. PMID: 28634044
  48. Results demonstrated that somatic mutation within E2F1:MIR136-5p target site impairs miRNA-mediated regulation and leads to increased gene activity. PMID: 28704519
  49. Specific E2Fs also have prognostic value in breast cancer, independent of clinical parameters. We discuss here recent advances in understanding of the RB-E2F pathway in breast cancer. We also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies. PMID: 26923330
  50. Results provide evidence that E2F1rs3213180 polymorphism may influence susceptibility to HPV-associated oral squamous cell carcinoma. particularly oropharynx tumors. PMID: 27677255

Show More

Hide All

Subcellular Location
Nucleus.
Protein Families
E2F/DP family
Database Links

HGNC: 3113

OMIM: 189971

KEGG: hsa:1869

STRING: 9606.ENSP00000345571

UniGene: Hs.654393

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*